Leadership & Pay ·
Keros Therapeutics, Inc. announced the resignation of Chief Financial Officer Keith Regnante, effective August 3, 2026
KROSKeros Therapeutics, Inc.
Keros Therapeutics, Inc. announced the resignation of Chief Financial Officer Keith Regnante, effective August 3, 2026. The company appointed Annita Tanini, currently the Company's Corporate Controller and Vice President, Finance, as interim principal financial officer and principal accounting officer, effective August 4, 2026. The company has commenced a search for a permanent Chief Financial Officer. Keros Therapeutics, Inc. is a biotechnology company focused on the development of therapies for inflammatory and inflammatory-related diseases.